Last 3,223 INR
Change Today +30.20 / 0.95%
Volume 338.6K
DRRD On Other Exchanges
Symbol
Exchange
New York
Natl India
Frankfurt
Mexico
As of 7:05 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
3,202
Previous Close
3,193
Day High
3,240
Day Low
3,149
52 Week High
09/19/14 - 3,240
52 Week Low
05/19/14 - 2,247
Market Cap
548.8B
Average Volume 10 Days
263.4K
EPS TTM
126.52
Shares Outstanding
170.3M
EX-Date
07/11/14
P/E TM
25.5x
Dividend
18.00
Dividend Yield
0.56%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

18,421 Employees
Last Reported Date: 06/26/14
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Managing Director, Chief Executi...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy's Mulls Acquisitions

Dr. Reddy's Laboratories Ltd. (BSE:500124) is seeking acquisitions. "We still continue to be interested in Japan. We are exploring all options. The priority is to get into the right plan to enter into the Japanese market. So the options for us are to seek a partner, acquire a company or do it organically," Dr Reddy's said.

Dr. Reddy's Involved in Discussion with US Consumer Product Safety Commission Regarding Alleged Packaging Safety Violations

A US Securities and Exchange Commission (SEC) filing from Dr. Reddy's indicates that the company is involved in discussion with the US Consumer Product Safety Commission (CPSC) regarding alleged packaging safety violations. The move follows a May 2012 request from the CPSC to Dr. Reddy's to supply information on compliance with child-resistant blister packaging requirements. Having reviewed this information, the CPSC wrote to Dr. Reddy's in April 2014 suggesting that the company had failed to comply with some packaging regulations. Dr. Reddy's disagrees with this conclusion and is currently in discussion with the CPSC. Dr. Reddy's has also suggested that the US Department of Justice (DoJ) is also investigating the CPSC's claims in relation to the False Claims Act.

Dr Reddy's Laboratories Appoints Sriram Gopalakrishnan as Director - Branding & Communications

Dr Reddy's Laboratories announced that Sriram Gopalakrishnan has been appointed as Director - Branding & Communications. He will be responsible for building Dr. Reddy's brand in Biosimilars, which is a strategic area of focus for the company, as the category is expected to grow significantly in the coming years. Prior to this, he was with the Indian School of Business (ISB) as Director - Marketing and Communication. At ISB, he was responsible for building greater global visibility and understanding of the ISB brand, and increasing the impact of marketing activities supporting all Programmes and Research Centres.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 3,222.95 INR +30.20

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 628.10 INR +8.05
Endo International PLC $67.70 USD +0.76
Lupin Ltd 1,401 INR +23.35
Sigma-Aldrich Corp $102.37 USD -0.93
Symrise AG €40.41 EUR +0.13
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 23.1x
Price/Sales 3.9x
Price/Book 5.6x
Price/Cash Flow 23.1x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.